Company Overview and News
Despite recent improvements, their 2017 Annual Report showed net sales down from $7,961 to $7,890 million and net cash provided by operating activities down from $1,491 to $1,291 million - Campbell's clearly has challenges.
DLTR GIS KHC PF MDLZ DIS
DEERFIELD, Ill., June 19, 2018 (GLOBE NEWSWIRE) -- Mondelēz International today announced that Luca Zaramella, 49, Senior Vice President of Corporate Finance and a 20-year veteran of the company, will become EVP, Chief Financial Officer (CFO), effective August 1, 2018.
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
In an effort to build an outstanding supply chain, Mondelez International, Inc. (MDLZ - Free Report) has invested $200 million in its Opava biscuit manufacturing facility ever since 2014. For the European market, this manufacturing unit produces Power Brands like Oreo, belVita, Milka and Cadbury. Notably, the company’s portfolio includes seven brands that generate revenues in excess of $1 billion and have been christened as Power Brands.
APRN SPG.PRJ DAR SPG MDLZ BGS
The table above is based on financial data included in the World Investment Report 2017, a report produced annually by the United Nations Conference on Trade and Development (UNCTAD) and just released with data for 2017. Table 19 of the UNCTAD report lists the world's top 100 non-financial "Multinational Enterprises" ranked by foreign assets in 2017, and the table above features the 20 multi-national corporations (MNCs) in that group that are headquartered in the US.
IBM GE PG XOM GOOG MDLZ DWDP GOOGL JNJ CVX AAPL KO INTC PFE ORCL
"The Nasdaq-100 Index includes 100 of the largest domestic and international non-financial companies listed on The Nasdaq Stock Market based on market capitalization." 52 pay dividends.
LRCX XLNX AMGN VOD VOD WYNN GILD CMCSA WBA WDC STX MDLZ HAS VODPF AMAT KHC CSCO QCOM PAYX
PENNSAUKEN, N.J., June 08, 2018 (GLOBE NEWSWIRE) -- J&J Snack Foods, the proud leader and innovator of the snack food & bakery industries, wants to see you at this year’s IDDBA show! Eager to announce new products and some new looks, there is a lot to be excited about! 2018 has brought J&J Snack Foods various changes; the introduction of new Sweet Stuffers® Premium Pastry Tarts, Labriola® Artisan Pretzel Breads, new manufacturing capabilities, and the rebrand and relaunch of an old favorite, Hill & Valley® Premium Bakery! You’re not going to want to miss out on this one!
DEERFIELD, Ill., June 07, 2018 (GLOBE NEWSWIRE) -- Mondelēz International today announced it has completed its previously announced acquisition of Tate’s Bake Shop, a fast-growing, premium cookie and baked goods brand known for its authentic, high-quality ingredients.
DEERFIELD, Ill., June 07, 2018 (GLOBE NEWSWIRE) -- Mondelēz International, Inc. today announced it will present at the Deutsche Bank Global Consumer Conference on Wednesday, June 13, at 6 a.m. EDT. Presenting on behalf of the company will be Executive Vice President and President, Mondelēz Europe Hubert Weber. A live audio webcast of the presentation will be available at https://edge.media-server.com/m6/p/z83t3z6n.
Chicago, IL – June 7, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Medifast, Inc. (MED - Free Report) , The Chefs' Warehouse, Inc. (CHEF - Free Report) and Conagra Brands, Inc. (CAG - Free Report) .
ALGN GIS BURL FIX MDLZ CHEF UFPI TIER PATK MED LULU PETS IO
The food industry has underperformed the broader market in a year’s time as the industry has been struggling in the face of numerous issues. Again, the industry currently ranks among the bottom 20% of all Zacks industries, signifying that industry-level factors will continue to be unfavorable. With obesity ballooning into a major heath issue in America, consumers are desperately looking for food with health benefits.
GIS MED MDLZ CHEF
Welcome to my second portfolio update of 2018. The goal of my portfolio is financial freedom. My plan is a combination of dividend growth investing and buying stocks that will beat the market. I call the DGI portion of my portfolio my "dividend machine", I do not DRIP, rather build up cash and actively make purchases when I see fit. The other part of my portfolio is looking for stocks with a strong risk/reward balance to generate alpha and beat the market.
NPSNY WFCNP FB PM SSNLF WFC.PRL BATS WFC.PRJ 4162 NVDA ABT WFC.PRT WFC.PRR WFC.PRQ NKE WFC.PRP WFC.PRO WFC.PRN AAPL OKE WFC.PRY WFC.PRX WFC.PRW MCD ABBV DEO WFC.PRV ABT WFC WFC.WS SQ GILD MDLZ V PEP JNJ KHC MSFT SBUX ABBV
Trade war fears between the United States and its trading partners have been rife since March. Trump’s announcement in early March that the United States will impose a 25% tariff on steel imports and a 10% tariff on aluminum imports first spooked the market.
LMT SOXX STZ.B FXG MDLZ STZ CARZ TSNU BOE XAR BA TSN HSY ITA
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET